Abstract 250P
Background
Adjuvant treatment for patients (pts) with endometrial cancer (EC) is decided based on risk assessment of recurrence and distant metastasis. Carcinomas of non-endometrioid (NE) histologies are rare, classified as high-risk and adjuvant treatment is recommended.
Methods
Retrospective analysis of EC pts diagnosed and treated in two units during 10 years (2009-2018) with a focus on pts with NEEC. After surgery and multidisciplinary discussion, pts had either no further treatment, radiotherapy (RT), chemotherapy (CT) followed by RT or CT. We compared these approaches using survival analysis.
Results
From a total of 330 pts with EC, 66 pts with surgery for NEEC were analyzed. Median age was 68.5 yrs (43-88). Serous histology was found in 34 (51.5%) pts, clear-cell in 13 (19.7%), in 18 (27.3%) carcinosarcoma and one pt had an undifferentiated tumor. Based on the International Federation of Gynecology and Obstetrics (FIGO) staging system, 32 pts (48.5%) were diagnosed at early stage (IA-II) and 34 (51,5%) at advanced stage (IIIA-IV). After surgery, 16 pts (24.4%) had no further treatment, while 11 (16.7%) received CT, 28 (42.4%) CT + RT and 11 (16.7%) only RT. RT included external beam RT and/or brachytherapy. In the survival analysis, the median DFS was significantly higher in the CT + RT group, 31 months (m), compared to both the RT alone group, 14m and the isolated CT group, 11m. For patients without further treatment DFS was 6m, p = 0.03. The median OS showed similar results: pts submitted to CT + RT had favorable survival (78m) compared to the other groups, RT group (64m), CT group (37m) and the group of pts with no further treatment (47m), p = 0.005.
Conclusions
The best survival results are for pts treated with CT+RT. Patients treated with RT had better results when compared with pts treated with CT or with pts without further treatment. These results show us that pts treated with CT are those with higher FIGO stages that were not considered for adjuvant RT. The worse survival results for untreated pts reflects deteriorated PS, extensive comorbidities or early progression. Due to aging and lifestyle risk factors, like obesity, EC remains the most prevalent gynecological carcinoma where better selection and implementation of adjuvant treatment modalities are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Author and co-authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract